Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
PMC
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Ghrelin and LEAP-2: Rivals in energy metabolism.
Trends Pharmacol. Sci. 39, 685-694 (2018)
Liver-expressed antimicrobial peptide 2 (LEAP-2), the endogenous noncompetitive allosteric antagonist of the growth hormone secretagogue receptor 1a (GHSR1a), was recently identified as a key endocrine factor regulating systemic energy metabolism. This antagonist impairs the ability of ghrelin to activate GHSR1a and diminishes ghrelin-induced Ca2+ release in vitro. The physiological relevance of the molecular LEAP-2-GHSR1a interaction was subsequently demonstrated in vivo. LEAP-2 is therefore a promising therapeutic target in the treatment of obesity and other metabolic diseases. Here, we discuss not only the current understanding of LEAP-2 in metabolic regulation, but also the potential of this peptide in the treatment of obesity and other diseases that involve dysregulation of the ghrelin system.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Gh ; Ghsr1a ; Leap-2 ; Food Intake ; Ghrelin ; Metabolic Syndrome; Des-acyl Ghrelin; Hormone Secretagogue Receptor; Healthy Older-adults; Diet-induced Obesity; Growth-hormone; Food-intake; Double-blind; Weight-loss; Glucose-metabolism; Gastric Bypass
ISSN (print) / ISBN
0165-6147
e-ISSN
1873-3735
Zeitschrift
Trends in Pharmacological Sciences
Quellenangaben
Band: 39,
Heft: 8,
Seiten: 685-694
Verlag
Cell Press
Verlagsort
Amsterdam
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Obesity (IDO)